Nurix Therapeutics Inc. (NRIX)
19.87
1.27 (6.83%)
At close: Jan 15, 2025, 1:42 PM
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Net Income | -143.95M | -180.36M | -117.19M | -43.24M | -21.70M | -9.43M |
| Depreciation & Amortization | 13.65M | 10.81M | 6.08M | 2.18M | 2.35M | 2.99M |
| Stock-Based Compensation | 33.67M | 28.13M | 15.80M | 4.30M | 510.00K | 431.00K |
| Other Working Capital | 18.51M | -25.11M | 6.75M | 35.17M | 19.24M | -24.79M |
| Other Non-Cash Items | -4.87M | 636.00K | 1.83M | 273.00K | -109.00K | -6.00K |
| Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -354.00K |
| Change in Working Capital | 20.12M | -19.02M | 9.11M | 36.41M | 19.55M | -25.31M |
| Operating Cash Flow | -81.36M | -159.81M | -84.36M | -80.00K | 601.00K | -31.68M |
| Capital Expenditures | -8.40M | -12.24M | -5.66M | -4.55M | -1.65M | -1.59M |
| Acquisitions | n/a | -39.44M | 102.59M | 249.85M | -10.15M | 6.00K |
| Purchase of Investments | -246.33M | -239.37M | -348.50M | -275.22M | -9.35M | -12.92M |
| Sales Maturities Of Investments | 323.04M | 278.81M | 245.91M | 25.37M | 19.50M | 54.50M |
| Other Investing Acitivies | n/a | 39.44M | -102.59M | -249.85M | 10.15M | 6.00K |
| Investing Cash Flow | 68.30M | 27.20M | -108.25M | -254.40M | 8.50M | 39.99M |
| Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | -16.00K | -2.00K |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 3.22M | 97.79M | 3.73M | 120.88M | 126.00K | 529.00K |
| Financial Cash Flow | 3.22M | 117.19M | 153.88M | 339.02M | 126.00K | 529.00K |
| Net Cash Flow | -9.85M | -15.42M | -38.73M | 84.54M | 9.22M | 8.85M |
| Free Cash Flow | -89.77M | -172.05M | -90.03M | -4.63M | -1.05M | -33.27M |